TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05233761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Defined CBD
Description: 300 mg CBD and 8 mg Terpenes administered as two small capsules.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules that smell and look exactly like Defined CBD but contain no CBD or terpenes.
Study: NCT06310798

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inter-professional team test
Description: Digital Platform Support is used to improve communication and collaboration between the different stakeholders involved in the care of older adults. This platform allows for the sharing of oral health assessments, plans, and recommendations, ensuring all parties have access to the same information and can contribute to the care planning process.~Person-Centered, Three-Step Model:~Initial oral health assessments conducted by dental professionals, A person-centered planning process where the needs and preferences of the older adults are prioritized, The implementation of tailored oral health care plans, emphasizing shared decision-making and the active involvement of older adults in their care.~Educational Component: An important element of the intervention is the provision of a two-day course for nursing and dental staff.
Study: NCT05458830

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Barrier Reduction Intervention
Description: After selecting a barrier in the barrier survey, participants receive tailored information with the purpose of addressing common concerns and misconceptions about the helpline.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Plain advisory text
Description: Care as usual
Study: NCT06270017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy drug
Description: rsponse evaluation in zebrafish embryo model
Study: NCT05767242

Intervention type: OTHER
Intervention: Electrophysiological recording
Description: Investigation of early neural markers using electrophysiology at 6-12-24 months

Intervention type: BEHAVIORAL
Intervention: Behavioral assessment
Description: Individual behavioral assessment at later ages (3, 4.5, 6, and 8 years)
Study: NCT06558188

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Romosozumab
Description: romosozumab 210 milligrams monthly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Romosozumab
Description: romosozumab 210 milligrams monthly
Study: NCT05465928

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active rTMS
Description: rTMS is a non-invasive neuromodulation therapy which has been recognized as a helpful treatment for depression. During each rTMS treatment, the magnetic field is generated by a coil which is placed on the head near the brain region of interest, and further, an electrical current is induced to modulate brain activity.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham rTMS
Description: The sham rTMS stimulation is performed based on a sham coil which will mimic scalp sensations and the acoustic artifact of the active stimulation, without delivering any magnetic pulse.
Study: NCT05725733

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: The participant will walk for 3-minutes at this speed as a warming up period. After these 3-minutes, the speed will be increased gradually up to 5-6 km/minute under the supervision of parents and therapist. The children will perform 10-minute running at this speed. After this, the cooling down exercise will be performed for 3-minutes. The speed will be decreased for 2 km/ minute and gradually stop.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: The participant will walk for 3-minutes at this speed as a warming up period. After these 3-minutes, the speed will be increased gradually up to 5-6 km/minute under the supervision of parents and therapist. The children will perform 10-minute running at this speed. After this, the cooling down exercise will be performed for 3-minutes. The speed will be decreased for 2 km/ minute and gradually stop.
Study: NCT06558188

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teriparatide
Description: teriparatide 20 micrograms daily
Study: NCT06199206

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Theraputic Play
Description: Before the procedures, therapeutic games will be played with the children and people of the intervention groups with eLPi dolls and other play materials prepared in accordance with anatomy. The parent will be with the child during this game, which will be played in his/her own room.
Study: NCT04848103

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Radial extracorporeal shockwave therapy
Description: Radial extracorporeal shockwave therapy group include Therapeutic modality(Transcutaneous electrical nerve stimulation \[TENS\], Microwave thermotherapy, and Superficial heat therapy), Range of motion exercise(Continuous passive motion and Active range of motion exercise).
Study: NCT04885634

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide Injectable Product
Description: Subcutaneous injection of Semaglutide 2.4 mg once weekly

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection of volume-matched placebo once weekly
Study: NCT06105112

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid
Description: Minimally invasive flap elevation and debridement of the intrabony defect with micro-curettes. Root surface debridement with ultrasonic debridement with periotip and mini-curettes. Application of cross-linked hyaluronic acid gel composed of a mixture of cross-linked (1.6%) and natural (0.2%) hyaluronic acid (hyaDent BG, Regedent, Germany) through a syringe over a bone xenograft (Smartgraft, Regedent, Germany). The mixture will be then compacted within the intrabony component of the defect.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Enamel matrix derivatives
Description: Minimally invasive flap elevation and debridement of the intrabony defect with micro-curettes. Root surface debridement with ultrasonic debridement with periotip and mini-curettes. Enamel matrix derivatives gel (Emdogain, Straumann, Switzerland) will be applied on the dry root surfaces and left in place for at least 1 minute avoiding blood contamination. Subsequently, a bone xenograft (Smartgraft, Regedent, Germany) will be compacted within the intrabony component of the defect.
Study: NCT06647056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: Administration of psilocybin 25 mg

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI
Description: Two standard MRI + fMRI scans before (D-3) and after (D5) treatment
Study: NCT06646081

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Greater Occipital Nerve Block
Description: The patient is placed prone with the head neutral or slightly flexed. After sterile preparation, a high-frequency linear probe is positioned transversely at the upper nuchal line in the occipital region. The Greater Occipital Nerve, exiting from the posterior root of C2, is located near the occipital artery. Using an in-plane technique, a 25-gauge needle is inserted into the fascial plane around the artery. After confirming no intravascular placement by negative aspiration, 5 mL of a mixture of 50 mg lidocaine and isotonic saline is injected. The fascial plane opening confirms the site. The area is dressed, and the patient is monitored for one hour for side effects.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stellate Ganglion Block
Description: The patient lies supine with a pillow under the shoulders, and the head slightly extended, neck gently turned opposite to the blockade. After sterile preparation, a high-frequency linear probe is placed transversely at the C6 vertebra (Chassaignac's tubercle). Ultrasound identifies the C6 vertebra, Longus colli muscle, carotid artery, and internal jugular vein. The Stellate Ganglion is located within the prevertebral fascia over the Longus colli. Using an in-plane technique, a 25-gauge needle is inserted and advanced into the prevertebral fascial plane. After confirming no intravascular placement by negative aspiration, 5 mL of 50 mg lidocaine and isotonic saline is injected. The fascial plane opening confirms the site. The area is dressed, and the patient is monitored for one hour for side effects.
Study: NCT05512234

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L. reuteri
Description: Dietary supplementation with drops containing L. reuteri once daily for 21 consecutive days

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dietary supplementation with placebo drops identical to those containing L. reuteri once daily for 21 consecutive days
Study: NCT05715047

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT for Fatigue
Description: 10, individualized counseling sessions with a behavioral health counselor via Zoom platform.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Standard transplant care.
Study: NCT05765253

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Scorpion Portal Vein Access Kit
Description: Portal Vein Access with Scorpion or Scorpion X set

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cook Transjugular Liver Access Set
Description: Portal Vein Access with Ring or Rosch-Uchida set

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transjugular Intrahepatic Portosystemic Shunt (TIPS)
Description: Transjugular Intrahepatic Portosystemic Shunt (TIPS)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transjugular Intrahepatic Portosystemic Shunt (TIPS)
Description: Transjugular Intrahepatic Portosystemic Shunt (TIPS)
Study: NCT04892602

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum vitaminDlevel
Description: Investigate about fibromyalgia in psoiaritic and rheumatiod arthritis patients ...and assesment of seum vitamin D level

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum vitaminDlevel
Description: Investigate about fibromyalgia in psoiaritic and rheumatiod arthritis patients ...and assesment of seum vitamin D level

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum vitaminDlevel
Description: Investigate about fibromyalgia in psoiaritic and rheumatiod arthritis patients ...and assesment of seum vitamin D level
Study: NCT04959825

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin 5 mg
Description: study the effect of preoperative oral melatonin 5mg on isoflurane consumption and postoperative pain

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar Coated Tablets
Description: the control group patients will receive placebo tablets one hour before induction of anesthesia
Study: NCT05113485

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diabetes Prevention Program-based lifestyle change intervention (DPP)
Description: The DPP condition consists of 11 health education sessions over 12 weeks, including 2 virtual home visits, two virtual group education sessions and 7 telephone coaching calls. These sessions will teach DPP-based lessons on how to lose excess body fat through calorie restriction and increased physical activity. All dietary and physical activity recommendations are intended to be consistent with federal nutrition and physical activity guidelines.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Highly Microbiota-Accessible Foods (HMAFs) intervention
Description: The Highly Microbiota-Accessible Foods (HMAFs) intervention approach includes 11 health education sessions, including two virtual home visits, two virtual group education sessions, and 7 telephone coaching sessions. These sessions are designed to help study participants to identify and consume optimally 6 daily instances of minimally processed, fiber-rich food sources, drawn from all four of the MyPlate.gov categories: vegetables, fruits, whole grains and plant-based protein-rich foods (e.g., legumes, nuts and seeds). Increased physical activity is also recommended as a way to optimize the microbial conversion of fiber-rich food sources to short chain fatty acids, which are then expected to reduce excess low-grade inflammation.
Study: NCT05515913

Intervention type: OTHER
Intervention: Nutritional status
Description: Nutritional status of children as analyzed by anthropometric indices was under study

Intervention type: OTHER
Intervention: Nutritional status
Description: Nutritional status of children as analyzed by anthropometric indices was under study

Intervention type: BEHAVIORAL
Intervention: Eating behavior
Description: The eating behavior of ASD children as analyzed by frequency of refusal of new food, sensitivity to food, food allergy and gastrointestinal systems was under study

Intervention type: OTHER
Intervention: Urine iodine concentration
Description: the 24 urine iodine concentration of all subjects was under study

Intervention type: OTHER
Intervention: Urine iodine concentration
Description: the 24 urine iodine concentration of all subjects was under study

Intervention type: OTHER
Intervention: Nutrient intake
Description: The nutrient intake as analyzed by three days food diary and major meal proximate analysis of subjects was under study

Intervention type: OTHER
Intervention: Nutrient intake
Description: The nutrient intake as analyzed by three days food diary and major meal proximate analysis of subjects was under study

Intervention type: OTHER
Intervention: Dietary assessment
Description: The food frequency and dietary diversity of all subjects as analyzed by food frequency questioner, dietary diversity score and food variety score was under study

Intervention type: OTHER
Intervention: Dietary assessment
Description: The food frequency and dietary diversity of all subjects as analyzed by food frequency questioner, dietary diversity score and food variety score was under study

Intervention type: OTHER
Intervention: Childhood autism rating scale
Description: The autistic severity of ASD diagnosed children was under study as analyzed by childhood autism rating scale diagnosis
Study: NCT05384236

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: kinesiology taping
Description: To apply kinesiology taping in plantar fascia

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: taping or Low-dye taping
Description: To apply taping or Low-dye taping in plantar fascia
Study: NCT04959500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Hydrochloride
Description: Drug: Anlotinib Hydrochloride Anlotinib hydrochloride will be given with a daily dose of 12 mg for 14 days of a 21-day cycle up to 2 cycles, initiated on the first day of radiation therapy and followed by adjuvant treatment with the same dosing schedule until patients have disease progression or intolerable toxicities.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Drug: Placebo Placebo will be given with a daily dose of 12 mg for 14 days of a 21-day cycle up to 2 cycles, initiated on the first day of radiation therapy and followed by adjuvant treatment with the same dosing schedule until patients have disease progression or intolerable toxicities.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Radiation: Radiation therapy Radiation therapy will be delivered in daily fractions of 1.8-2.0 Gy given 5 days a week for a total of 54-60 Gy.

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Radiation Therapy
Description: Radiation: Radiation therapy Radiation therapy will be delivered in daily fractions of 1.8-2.0 Gy given 5 days a week for a total of 54-60 Gy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Drug: Temozolomide Temozolomide will be administered at a daily dose of 75 mg/m2 until the completion of radiation therapy. Four weeks after the completion of radiation therapy, patients will be given with adjuvant chemotherapy with temozolomide at a dose of 200 mg/m2 for 5 days of a 28-day cycle for a total of 6 cycles.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Temozolomide
Description: Drug: Temozolomide Temozolomide will be administered at a daily dose of 75 mg/m2 until the completion of radiation therapy. Four weeks after the completion of radiation therapy, patients will be given with adjuvant chemotherapy with temozolomide at a dose of 200 mg/m2 for 5 days of a 28-day cycle for a total of 6 cycles.
Study: NCT05955755

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: butterfly vacuum blood collection set
Description: Blood collection from the children in the experimental group will be performed with a butterfly vacuum blood collection set.
Study: NCT02950688

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Seasonal LAIV
Description: 10\^7.0 fluorescent focus units (FFU); administered by intranasal spray

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by intranasal spray

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Wild-type A/California/2009-like Influenza Virus
Description: Approximately 3.5 x 10\^6 TCID50; administered intranasally

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Wild-type A/California/2009-like Influenza Virus
Description: Approximately 3.5 x 10\^6 TCID50; administered intranasally
Study: NCT04291703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antithymocyte Globulin
Description: Thymoglobulin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for ATG)
Description: Normal Saline administered by IV infusion to mimic ATG
Study: NCT05582590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lymphodepletion Chemotherapy on Days -5, -4, and -3 before Cycle 1 ONLY

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lymphodepletion Chemotherapy on Days -5, -4, and -3 before Cycle 1 ONLY

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lymphodepletion Chemotherapy on Days -5, -4, and -3 before Cycle 1 ONLY

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lymphodepletion Chemotherapy on Days -5, -4, and -3 before Cycle 1 ONLY

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lymphodepletion Chemotherapy on Days -5, -4, and -3 before Cycle 1 ONLY

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lymphodepletion Chemotherapy administered on Days -5, -4, and -3 before Cycle 1 ONLY

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lymphodepletion Chemotherapy administered on Days -5, -4, and -3 before Cycle 1 ONLY

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lymphodepletion Chemotherapy administered on Days -5, -4, and -3 before Cycle 1 ONLY

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lymphodepletion Chemotherapy administered on Days -5, -4, and -3 before Cycle 1 ONLY

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lymphodepletion Chemotherapy administered on Days -5, -4, and -3 before Cycle 1 ONLY

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NEXI-003 T cells
Description: Adoptive Cell Therapy specified dose on specified day(s)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NEXI-003 T cells
Description: Adoptive Cell Therapy specified dose on specified day(s)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NEXI-003 T cells
Description: Adoptive Cell Therapy specified dose on specified day(s)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NEXI-003 T cells
Description: Adoptive Cell Therapy specified dose on specified day(s)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NEXI-003 T cells
Description: Adoptive Cell Therapy specified dose on specified day(s)
Study: NCT06143254

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Infant sign training
Description: Training session 1: Information is given about what infant signs are, how they originated, how speech and (gestural) language develop in young children with CP ± L, the possible advantages of using infant signs and tips for success. Twelve signs are chosen to start with: six narrative signs (mostly object concepts) and six steering signs (mostly non-object concepts). Training session 2: Experiences with using infant signs at home are shared, repetition of the 12 infant signs and tips for success are discussed. Another 12 signs are chosen to add to the repertoire the caregivers can use, based on caregiver input. Training session 3: The same as training session 2. The content is based on the input the caregivers experience. Another 12 signs are chosen to add to the repertoire the caregivers can use, based on caregiver input. Reading aloud while using infant signs is shown and practiced.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Verbal training
Description: Training session 1: Information is given about how speech and language develop in young children with CP ± L and how caregivers can support their child during this development Tips for success and suggestions on how to use these supportive verbal techniques at home are discussed. Training session 2: Experiences with using supportive verbal techniques at home are shared and supportive verbal techniques repeated. Information is provided about how children learn new words and tips for success are expanded. Training session 3: The same as training session 2. The content is based on the input the caregivers experience. Additionally, advances of reading aloud are discussed and reading aloud is practiced.
Study: NCT05763368

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Clinical tests and proprioception evaluation
Description: Each patient will be evaluated using clinical scales (BBS, HHS, HOOS, SF12) and ''Delos Proprioceptive System'' to assess postural stability and proprioception.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Clinical tests and proprioception evaluation
Description: Each patient will be evaluated using clinical scales (BBS, HHS, HOOS, SF12) and ''Delos Proprioceptive System'' to assess postural stability and proprioception.
Study: NCT05245734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Anti-D (rh) immunoglobulin
Description: prevention of Rh-sensitization in pregnant women in the antenatal and postnatal period in routine clinical practice. The study drug is administered twice at a dose of 300 mcg - at 28 weeks of gestation and within 72 hours after delivery.
Study: NCT04973241

Intervention type: RADIATION
Intervention: OPG & CBCT
Description: panoramic images , cone beam computed tomography

Intervention type: RADIATION
Intervention: OPG & CBCT
Description: panoramic images , cone beam computed tomography
Study: NCT04850573

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: equine assisted activities
Description: Participants interact with the horse and learn how to safely handle the horse.